AAAAAA

   
Results: 1-25 | 26-32
Results: 1-25/32
Correspondence re: C. F. M. Sier et al., enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: A comparison with clinically used tumor markers. Clin. Cancer Res., 6 : 2333-2340, 2000.
Authors: Gerhards, S Jung, K Koenig, F Daniltchenko, D Hauptmann, S Schnorr, D Loening, SA
Citation: S. Gerhards et al., Correspondence re: C. F. M. Sier et al., enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: A comparison with clinically used tumor markers. Clin. Cancer Res., 6 : 2333-2340, 2000., CLIN CANC R, 7(2), 2001, pp. 445-446
Tumor M2 pyruvate kinase in plasma of patients with urological tumors
Authors: Roigas, J Schulze, G Raytarowski, S Jung, K Schnorr, D Leoning, SA
Citation: J. Roigas et al., Tumor M2 pyruvate kinase in plasma of patients with urological tumors, TUMOR BIOL, 22(5), 2001, pp. 282-285
Moving beyond a deficit model to describe and promote the career development of at-risk youth
Authors: Schnorr, D Ware, HW
Citation: D. Schnorr et Hw. Ware, Moving beyond a deficit model to describe and promote the career development of at-risk youth, J CAREER D, 27(4), 2001, pp. 247-263
Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis
Authors: Lein, M Jung, K Elgeti, U Petras, T Stephan, C Brux, B Sinha, P Winkelmann, B Schnorr, D Loening, SA
Citation: M. Lein et al., Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis, EUR UROL, 39(1), 2001, pp. 57-64
A Multicenter Clinical Trial on the use of alpha(1)-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis
Authors: Lein, M Jung, K Hammerer, P Graefen, M Semjonow, A Stieber, P Ossendorf, M Luboldt, HJ Brux, B Stephan, C Schnorr, D Loening, SA
Citation: M. Lein et al., A Multicenter Clinical Trial on the use of alpha(1)-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis, PROSTATE, 47(2), 2001, pp. 77-84
Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms - What hasto be considered?
Authors: Jung, K Stephan, C Lein, M Brux, B Sinha, P Schnorr, D Loening, SA
Citation: K. Jung et al., Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms - What hasto be considered?, PROSTATE, 46(4), 2001, pp. 307-310
Excretion of matrix metalloproteinases 2 and 9 in urine is associated witha high stage and grade of bladder carcinoma
Authors: Gerhards, S Jung, K Koenig, F Daniltchenko, D Hauptmann, S Schnorr, D Loening, SA
Citation: S. Gerhards et al., Excretion of matrix metalloproteinases 2 and 9 in urine is associated witha high stage and grade of bladder carcinoma, UROLOGY, 57(4), 2001, pp. 675-679
Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen < 4 mu g/L: Are they useful tools for early detection and screening of prostate cancer?
Authors: Jung, K Stephan, C Elgeti, U Lein, M Brux, B Kristiansen, G Rudolph, B Hauptmann, S Schnorr, D Loening, SA Sinha, P
Citation: K. Jung et al., Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen < 4 mu g/L: Are they useful tools for early detection and screening of prostate cancer?, INT J CANC, 93(5), 2001, pp. 759-765
Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer
Authors: Jung, K Lein, M von Hosslin, K Brux, B Schnorr, D Loening, SA Sinha, P
Citation: K. Jung et al., Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer, CLIN CHEM, 47(11), 2001, pp. 2061-2063
MRI of the prostate after combined radiotherapy (interstitial with external beam irradiation): Histopathological correlation.
Authors: Beyersdorff, D Taupitz, M Deger, S Rudolph, B Dinges, S Schnorr, D Loening, S Hamm, B
Citation: D. Beyersdorff et al., MRI of the prostate after combined radiotherapy (interstitial with external beam irradiation): Histopathological correlation., ROFO-F RONT, 172(8), 2000, pp. 680-685
Staging of urinary bladder tumors by MRI: Utility of intravesical administration of an iron oxide-containing contrast medium in combination with high-resolution, T-2-weighted imaging.
Authors: Beyersdorff, D Taupitz, M Giessing, M Turk, I Schnorr, D Loening, S Hamm, B
Citation: D. Beyersdorff et al., Staging of urinary bladder tumors by MRI: Utility of intravesical administration of an iron oxide-containing contrast medium in combination with high-resolution, T-2-weighted imaging., ROFO-F RONT, 172(6), 2000, pp. 504-508
Elimination of serum complexed prostate-specific antigen after radical retropubic prostatectomy
Authors: Stephan, C Jung, K Brux, B Lein, M Sinha, P Schnorr, D Leoning, SA
Citation: C. Stephan et al., Elimination of serum complexed prostate-specific antigen after radical retropubic prostatectomy, CLIN CH L M, 38(4), 2000, pp. 309-311
Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions
Authors: Jung, K Lein, M Brux, B Sinha, P Schnorr, D Loening, SA
Citation: K. Jung et al., Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions, CLIN CH L M, 38(12), 2000, pp. 1271-1275
Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer
Authors: Stephan, C Jung, K Lein, M Sinha, P Schnorr, D Loening, SA
Citation: C. Stephan et al., Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer, CANC EPID B, 9(11), 2000, pp. 1133-1147
Tumor M2 pyruvate kinase in renal cell carcinoma. Patient plasma examination
Authors: Roigas, J Schulze, G Raytarowski, S Jung, K Schnorr, D Loening, SA
Citation: J. Roigas et al., Tumor M2 pyruvate kinase in renal cell carcinoma. Patient plasma examination, UROLOGE A, 39(6), 2000, pp. 554-556
Molecular forms of prostate-specific antigens and human kallikrein 2 as possible indicators in prostate cancer diagnostics
Authors: Lein, M Stephan, C Jung, K Schnorr, D Loening, SA
Citation: M. Lein et al., Molecular forms of prostate-specific antigens and human kallikrein 2 as possible indicators in prostate cancer diagnostics, UROLOGE A, 39(4), 2000, pp. 313-323
Genetic analysis of Tp53 from urine sediment as a tool for diagnosing recurrence and residual of bladder carcinoma
Authors: Sachs, MD Schlechte, H Lenk, VS Brenner, S Schnorr, D Fleige, B Ditscherlein, G Loening, S
Citation: Md. Sachs et al., Genetic analysis of Tp53 from urine sediment as a tool for diagnosing recurrence and residual of bladder carcinoma, EUR UROL, 38(4), 2000, pp. 426-433
Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model
Authors: Lein, M Jung, K Le, DK Hasan, T Ortel, B Borchert, D Winkelmann, B Schnorr, D Loenings, SA
Citation: M. Lein et al., Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model, PROSTATE, 43(2), 2000, pp. 77-82
Ratio of alpha1-antichymotrypsin - Prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis
Authors: Lein, M Jung, K Elgeti, U Brux, B Sinha, P Schnorr, D Loening, SA
Citation: M. Lein et al., Ratio of alpha1-antichymotrypsin - Prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis, ANTICANC R, 20(6D), 2000, pp. 4997-5001
ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: Proof of new complex forming of PSA after release into circulation
Authors: Stephan, C Jung, K Brux, B Lein, M Sinha, P Schnorr, D Loening, SA
Citation: C. Stephan et al., ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: Proof of new complex forming of PSA after release into circulation, UROLOGY, 55(4), 2000, pp. 560-563
Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
Authors: Stephan, C Jung, K Lein, M Schnorr, D Leoning, SA
Citation: C. Stephan et al., Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer, J UROL, 164(5), 2000, pp. 1671-1671
Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma
Authors: Lein, M Jung, K Laube, C Hubner, T Winkelmann, B Stephan, C Hauptmann, S Rudolph, B Schnorr, D Loening, SA
Citation: M. Lein et al., Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma, INT J CANC, 85(6), 2000, pp. 801-804
Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: Biochemical and diagnostic implications
Authors: Jung, K Brux, B Lein, M Rudolph, B Kristiansen, G Hauptmann, S Schnorr, D Loening, SA Sinha, P
Citation: K. Jung et al., Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: Biochemical and diagnostic implications, CLIN CHEM, 46(1), 2000, pp. 47-54
Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Authors: Jung, K Elgeti, U Lein, M Brux, B Sinha, P Rudolph, B Hauptmann, S Schnorr, D Loening, SA
Citation: K. Jung et al., Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?, CLIN CHEM, 46(1), 2000, pp. 55-62
Urinary markers of malignancy
Authors: Koenig, F Jung, K Schnorr, D Loening, SA
Citation: F. Koenig et al., Urinary markers of malignancy, CLIN CHIM A, 297(1-2), 2000, pp. 191-205
Risultati: 1-25 | 26-32